Filamentous phage displaying peptides representing single epitopes of the glycoprotein G of HSV-2 (gG2) were used as immunogens via the subcutaneous route in Balb/c mice without additional adjuvant. The phage were isolated from a random phage peptide display library and contain 15-mer peptide inserts that mimic epitopes of gG2. In each case, an antibody response to gG2 was generated that was dependent on the dose of phage administered and on the presence of the peptide insert. Phage displaying epitopes of gG2, which map to amino acids 551-570, were the most immunogenic; interestingly, this region of gG2 is frequently recognised by patients infected with HSV-2. The data also provide interesting information as regards choice of peptide mimics for use as immunogens because, surprisingly, the most antigenic of the individual clones was the least immunogenic. In two of the experiments, mice immunised with phage displaying a single epitope of gG2 were protected against challenge with a lethal dose of whole HSV-2. This suggests a possible role for phage-displayed peptides in inducing protective immunity against pathogens and provides a model system for investigating the underlying mechanisms.
INTRODUCTION
Filamentous bacteriophage may be engineered to express peptides as N-terminal fusions of the coat proteins pIII and pVIII. Whereas pIII is present in only five copies per virion, pVIII is represented by 2700 copies and is a more favoured site for the introduction of peptides for the purpose of immunisation (Willis et al., 1993; Veronese et al., 1994; Meola et al., 1995) . The N-terminal 20 amino acids of pVIII are exposed on the surface of the phage. Small peptides, up to ϳ5 amino acids in length, can be inserted close to the N terminus without disrupting phage assembly (Greenwood et al., 1991) . However, insertion of larger peptides can only be achieved using a phage construct with two copies of gene VIII, one encoding the wild-type protein and a second encoding pVIII displaying the insert peptide. Both are incorporated in the phage particle with the recombinant pVIII accounting for Յ30% of the expressed protein.
To date, studies of natural and experimentally induced immunity to herpes simplex virus (HSV) have revealed a complex picture involving multiple proteins such as gB and gD (Stanberry, 1995; McKenzie and Straus, 1996) , and the likely involvement of cell-mediated as well as antibody-mediated immunity in protection against primary infection or reactivation (Watari et al., 1998; Brehm et al., 1997) . Accordingly, attempts to develop a vaccine against HSV type 2 (HSV-2) have focused on live attenuated virus containing whole virion particles or whole proteins. We have previously identified phage clones that express peptides that mimic single epitopes of the glycoprotein G of HSV-2, gG2 (Grabowska et al., 1999) . We now report the observation that these relatively simple peptide antigens, fused to phage virions, confer protective immunity in a live challenge model of HSV-2 infection. This is the first demonstration that peptides discovered and displayed on phage can be used to confer protective immunity against an infectious agent and support the view that this approach may be generally useful as a discovery and delivery tool for the development of novel vaccines.
RESULTS
In an initial experiment, eight groups of three mice were immunised on two occasions with a pool of three phage clones, 2.10, 2.11, and 3.19. These phage had been previously selected by biopanning a phage library against the anti-gG2 monoclonal antibody (mAb), H5 (Grabowska et al., 1999) . Each clone displays a different peptide ( Table 1 ) that represents the epitope of gG2 recognised by H5. The phage were prepared individually by polyethylene glycol (PEG) precipitation and pooled; half of the pool was absorbed against polymixin B to remove contaminating lipopolysaccharide (LPS), which may be toxic to mice. Both of these preparations were used as immunogens at one of four doses (100, 75, 50, or 10 g). The antibody response to wild-type phage and gG2 in each group of mice was measured by ELISA in prebleeds and in sera obtained from blood collected 2 weeks following the last immunisation. The results are shown in Figs. 1a and 1b. Antibodies to both wild-type phage (f88-4) and gG2 could be detected in a number of mice in each group. In general, there was a stronger response in the mice immunised with unabsorbed compared with absorbed phage, and a larger dose of immunogen gave rise to a higher level of antibodies. The percentage survival within each group, 14 days after lethal challenge, is shown in Fig. 1c . At the two highest phage doses (100 and 50 g) all mice survived, and with decreasing phage doses survival decreased, suggesting that protective immunity to HSV-2 can be induced by immunisation with phage clones displaying peptides that mimic a single epitope of gG2. Because no toxic effects attributable to LPS were observed, all remaining experiments were carried out with phage that had not been absorbed against polymixin B.
Three additional experiments were carried out to further investigate the ability of phage-displayed peptides to stimulate production of antibodies to gG2 and to protect against lethal challenge with HSV-2. In each experiment, groups of 10 mice were given three immunisations at 2-week intervals with phage displaying epitopes derived from gG2, as follows: (a) the pool of H5 phage clones (2.10, 2.11, and 3.19) at doses ranging between 1 and 300 g. (b) three pools of phage clones, each at 30 or 100 g, representing epitopes defined by other gG2 mAbs (H7, F11, and E5, respectively): 7.17 and 7.25; 8. 13, 8.22, and 9.4; and 12.4, 12.18, and 12.28. (c) Individual phage clones from the H5 pool, each at 30 or 100 g.
In addition, groups were immunised with wild-type phage (f88-4) to ensure that the response generated was dependent on the peptide insert displayed by the phage or with Tris-buffered saline (TBS) as a control for the lethal challenge. In both (b) and (c), mice immunised with the H5 pool were also included to allow comparison between experiments. Figure 2 shows the reactivity of sera from these mice with gG2. In comparison with the level of response in the prebleeds, a clear dose-dependent response to the phagedisplayed peptides was observed, with saturation of the response at a dose of 100 g (Fig. 2a) . Some reactivity to gG2 could be detected in mice immunised with f88-4, but this response was low compared with the level of antibody generated in response to the same dose of phage displaying H5-reactive peptides. Phage displaying the H7, F11, and E5 epitopes were also immunogenic, especially at the 100-g dose, but while the response to the E5 pool of phage was comparable to that observed for the H5 pool, a lower response to the H7 and F11 pools was found (Fig. 2b) . When individual clones from the H5 pool were tested, there was again a clear hierarchy of immunogenicity with clone 3. 19 being the most immunogenic and 2. 10 the least (Fig.  2c ). This was a surprising result given the relative antigenicity of the phage clones as measured by their binding of H5 in ELISA (Fig. 3a) , though this may relate to the apparently high level of expression of the recombinant pVIII in this clone as analysed by silver staining of Tris-tricine gels (Fig. 3b) . 
Note. For each phage clone, the sequence of the 15 amino acid peptide, expressed as an insert in the phage major coat protein, is given using the standard single letter amino acid code. In addition, for each mAb the motif common to phage clones selected by the mAb and the gG2 sequence shown to contain the epitope is shown. Lower case numbers on the "native" sequence lines indicate amino acid positions within gG2
Following each of these immunisation experiments, the mice were again challenged with a lethal dose of HSV-2 and monitored over the following 14 days. In the groups immunised with a range of doses of phage displaying H5-reactive peptides protection was sporadic, and similar or higher levels of survival were observed in the groups immunised with wild-type phage. High levels of survival (Ͼ70%) were seen in the experiment in which mice were immunised with phage displaying peptides representing other epitopes of gG2 in both test and control groups, suggesting that the challenge dose of virus was inadequate, and thus no conclusions could be drawn as to the efficacy of these immunogens in providing protection. However, in the final experiment in which groups of mice were immunised with phage displaying H5-reactive peptides, differences in the survival rates
Anti-gG2 responses measured by ELISA for mice immunised with a range of doses of the H5 pool of clones (a); three further pools of phage clones displaying epitopes defined by the anti-gG2 mAbs H7, F11, or E5 (b); individual phage clones 2.10, 2.11, or 3.19 from the pool of H5 clones (c). Control immunogens included the wild-type phage f88-4 and TBS. Each point represents the result for an individual animal. For each group, the median of the responses of individual animals within that group is shown as a horizontal line.
FIG. 1.
The antibody response to wild-type phage (a) or gG2 (b) measured by ELISA and the percentage survival within each group of mice 14 days after challenge with a lethal dose of HSV-2 (c) are shown. Mice were immunised with a range of doses of the pool of phage clones (2.10, 2.11, and 3.19) displaying phage representing the H5 epitope of gG2. The phage preparation was either used immediately following PEG precipitation (unabsorbed) or following absorption against polymixin B to remove LPS (absorbed). Each point represents the result for an individual animal.
between the control groups and the experimental groups could be seen. The survival of each of the groups of mice in this experiment over the 17 days following lethal challenge is shown in Fig. 4 . At the end of the 17-day period, only 20% of the mice in the control groups, immunised with wild-type phage or TBS, were still alive, in contrast with 40-60% of the mice immunised with individual phage clones or 100 g of pooled phage and 80% of mice given 30 g of the pool of phage. For this experiment, the survival times of mice immunised with 100 or 30 g of phage displaying HSV peptides were compared with those of mice receiving 100 or 30 g of wild-type phage, respectively, or TBS only, using the Mann-Whitney test. Statistical significance (P Յ 0.05) was achieved when the group immunised with 30 g of the pool of phage was compared with those receiving 30 g of wild-type phage or TBS alone and when the group receiving 100 g 2.10 was compared with those receiving 100 g wild-type phage or TBS alone. The comparisons were also approaching significance (P Ͻ 0.1) for the groups immunised with 100 g of 2.11 and 100 g of the pool of phage.
DISCUSSION
Immunisation of mice with pools of phage clones, or individual phage clones, displaying 15 amino acid peptides representing single epitopes of gG2 resulted in a serum antibody response to gG2. The level of the antigG2 antibody response observed was dependent on the phage dose administered and increased with successive immunisations (data not shown). The anti-gG2 reactivity of sera from mice immunised with equivalent doses of the wild-type phage f88-4 was low; this shows that the response to the phage displaying gG2 epitopes is due to the displayed epitopes rather than components of the phage. The peptides displayed by the phage are, therefore, not only antigenic, i.e., able to mimic this gG2 epitope, but are also immunogenic.
The peptides displayed by these phage are not derived from the native sequence of gG2. The phage clones were selected from a random phage peptide display library by four mouse monoclonal antibodies and mimic four discrete epitopes of gG2 (Grabowska et al., 1999) . The phage selected by mAbs H5, E5, and F11 display peptides with some similarity to the native sequence of gG2 over only part of their length, approximately 3-5 amino acids (see Table 1 ). Therefore the majority of the amino acids within the 15 amino acid peptide inserts are not part of the epitopes though they may be required to maintain the antigenicity or immunogenicity of the peptide, for example, by contributing to the folding of the peptide. Different degrees of immunogenicity were observed with different phage clones or pools of clones. Interestingly, the H5 and E5 clones, both derived from a region of gG2 (amino acids 551-570) that is recognised by a large proportion of patients infected with HSV-2 (Marsden et al., 1998; Grabowska et al., 1999) , were the most immunogenic, though antibodies were also generated in response to the F11 and H7 clones, which map to amino acids 351-427 and amino acids 569-588 of gG2, respectively (Grabowska et al., 1999) . The three H5 clones were also used individually as immunogens. Surprisingly, the phage clone 2.10, which is the most antigenic, as defined by its reactivity with mAb H5 in ELISA, was the least immunogenic. This may be accounted for by the apparently low level of expression of the recombinant peptide-displaying pVIII in this phage clone because the most immunogenic of the clones, 3.19, had the highest level of expression of the recombinant pVIII; however, one would expect that low levels of expression would also adversely affect the antigenicity of clone 2.10.
In these experiments, phage were administered without any additional adjuvant. The phage preparations used are likely to contain some bacterial contaminants. It will be of interest to find out whether these or components of the phage itself are able to provide an adjuvant effect. Certainly the overall levels of antibody were lower in mice given phage preparations that had been preabsorbed against polymixin B to remove LPS. Willis et al. (1993) , showed that the immune response to phagedisplayed peptides was T-cell dependent. Presumably, this T-cell help is provided by components of the phage or bacterial contaminants and may be involved in directing the immune response towards a Th1 or Th2 type of response.
In two of the experiments, protection against lethal challenge with HSV-2 was observed. In one experiment, protection correlated well with the dose of the H5 pool of phage used, with 100% of the mice receiving the highest doses surviving beyond Day 14 and lower survival rates in groups of mice receiving lower doses. In another experiment, again using the H5 phage clones, as a pool or as individual clones, while the overall survival rates were lower, the protection observed was dependent on the presence of the insert peptide because use of wildtype phage gave rise to lower levels of survival equivalent to those in mice immunised with buffer alone. However, this effect was difficult to reproduce; in one of the two remaining experiments, survival levels were high in all groups possibly because the lethal challenge dose used was too low, and in the other, the protection was inconsistent with no correlation between protection and either the dose or nature of the immunogen. In addition, in the experiments where protection was observed, there was no obvious correlation between the level of antibody to gG2 induced and the degree of protection: animals receiving the unabsorbed phage preparation and those receiving a preparation preabsorbed against polymixin B to remove LPS were protected, even though the levels of antibody generated in the latter were considerably lower; and protection was highest in mice that had been given a 30-g dose of the pool of H5 phage (Fig. 4) , while stronger anti-gG2 responses were seen in other groups that had lower survival rates (Fig. 2c) .
It is possible that, to some extent, the variability in the protection is related to use of different phage preparations with differing degrees of bacterial contamination in different experiments. If such molecules do provide an adjuvant effect, there may be subtle differences between the anti-gG2 responses generated in different experiments, for example, in the relative proportions of different isotypes of antibodies. Cell-mediated immune mechanisms have also been shown to contribute to protection against HSV-2 infection (Schmid and Rouse, 1992) ; in the present study, measurement of cellular immune responses was not attempted because these phage do not contain significant lengths of sequence derived from the native protein, and therefore it seemed unlikely that the mechanism involved in the observed protection is cellmediated; however, this remains to be formally proven. Because this is a biological model, it is also possible that variation between the experiments in terms of the survival observed is related to other factors that affect susceptibility of the mice to lethal challenge such as minor differences in age and size of the animals and the dose of virus used for the lethal challenge.
While it has been shown previously that phage expressing peptides derived from viral proteins (Willis et al., 1993; Veronese et al., 1994) or expressing mimotopes of epitopes from viral proteins are able to induce an antibody response to the native protein (Meola et al., 1995) , it has not been demonstrated previously that they can induce protection against challenge with virus. It is striking that phage displaying single epitopes are able to induce protection against a whole virus. Here we have achieved similar levels of protection to those achieved previously using a whole baculovirus-expressed glycoprotein G (Ghiasi et al., 1992) .
There has been considerable interest in the use of glycoproteins derived from HSV-2 as subunit vaccines for use in humans both to protect against HSV-2 infection and to reduce the frequency and severity of recurrent episodes of disease (Stanberry, 1995; McKenzie and Straus, 1996) . Previous work with candidate subunit HSV vaccines has concentrated on the glycoproteins B and D as these contain numerous type-common epitopes and, thus, are likely to stimulate protection against both HSV-1 and HSV-2. The experiments described here suggest that the glycoprotein G is a potential vaccine candidate. The present study also has implications for the development of a prophylactic vaccine against HSV-2. The current study emphasises the likely importance of type-specific antibodies in protection against primary infection by HSV-2, as observed in previous studies of protection against neonatal infection by transplacentally acquired maternal antibodies (Ashley et al., 1992) , and suggests novel approaches to the development of an HSV-2 vaccine that focuses the attention of the immune system on type-specific epitopes even in the context of an immune system primed to respond to type-common epitopes.
The experiments we have described may provide a model system for investigating the potential role of phage in inducing protective immunity against pathogens and the immune mechanisms that are involved in conferring this protection. However, further studies are required to identify the factors involved such as the isotypes of antibody produced, and the role of bacterial and phage proteins in providing an adjuvant effect.
MATERIALS AND METHODS

Phage clones
Phage clones were isolated from a phage peptide display library, based on the filamentous phage fd, consisting of ϳ10 8 different phage clones, each displaying a 15 amino acid peptide as part of their major coat protein (Grabowska et al., 1999) . In addition to a wild-type gene VIII encoding the major coat protein pVIII, the phage in this library were engineered to express a recombinant form of gene VIII containing a degenerate DNA insert encoding random peptides and are, therefore, Type 88 vectors (Smith, 1993) . The recombinant gene VIII is under the control of a tac promoter; the ratio of the peptidedisplaying to wild-type pVIII can, therefore, be altered by varying the concentration of iso-propyl-thio-galactose (IPTG) added to the host bacterial culture.
Eleven phage clones recognised by 4 mAbs (Liljeqvist et al., 1998) were used: 2.10, 2.11, and 3.19 recognised by mAb H5; 7.17 and 7.25, mAb H7; 8.13, 8.22, and 9.4, mAb F11; and 12.4, 12.18 , and 12.28, mAb E5. Identification and characterisation of these clones is described in detail in Grabowska et al. (1999) . The sequences of the peptides displayed by these phage clones are given in Table 1 . In addition, the wild-type phage, f88-4 from which the library was derived, was used.
Preparation of PEG-precipitated phage for use as immunogens
Phage clones were prepared from a 500-ml overnight culture of infected bacteria grown in Terrific Broth with tetracycline (20 g/ml) to select for phage expression and IPTG (1 mM) to maximise expression of the recombinant gene VIII carrying the peptide insert. f88-4 was grown in the absence of IPTG as no peptide is displayed by the recombinant gene VIII.
Bacteria were removed by centrifugation at 10,000 g maximum in a Sorvall GSA rotor at 4°C. Phage were precipitated from the supernatant by addition of PEG 8000 and NaCl to final concentrations of 4% and 3%, respectively, followed by a 45-min incubation at room temperature with stirring. The phage were pelleted by centrifugation at 10,000 g at 4°C. The supernatant was discarded, and the phage pellet was resuspended in TBS. Insoluble material was removed by a further centrifugation at 10,000 g. The PEG precipitation was then repeated.
Phage concentration was assessed using the Sigma BCA assay, using ovalbumen as a standard, according to the manufacturer's instructions.
Polymixin B absorption of PEG precipitated phage
For some phage preparations, LPS was absorbed out of the PEG precipitated phage preparations by passing them through polymixin B columns (Pierce).
Immunisation BALB/c mice were obtained from a randomly bred, closed colony at the Sheffield University animal facility. Immunisations were administered subcutaneously at 2-week intervals. The dose given is the quantity of phage used per mouse per immunisation in a 200 ml volume of TBS. Prebleeds were obtained from a random selection of the mice prior to immunisation, and further bleeds were taken from all mice 2 weeks after each immunisation. Four weeks after the last immunisation, mice were challenged with 5-6 mouse lethal doses of HSV-2 (strain 333). Survival of the mice was monitored daily.
Analysis of immune response to gG2 by ELISA Wells were coated with Helix pomatia lectin purified gG2 (gift from Dr. S. Jeansson, Oslo, Norway) at a dilution of 1:500 in carbonate-bicarbonate buffer, pH 9.6, blocked with 30% normal goat serum (NGS) in phosphate-buffered saline (PBS), then incubated in turn with mouse sera at a 1:100 dilution and horseradish peroxidase conjugated rabbit anti-mouse Ig at 1:1000 in PBS-10% NGS.
After each step, wells were washed with PBS containing 0.05% Tween 20. Fast OPD tablets (Sigma) were used as a substrate for the peroxidase and the O.D. of each well was read at 490 nm after stopping the reaction with 2 M H 2 SO 4 .
For each experiment, a random selection of sera from groups of mice immunised with phage-displayed peptides were analysed for their immune response to gG2, by titration of the sera. Based on the result of this initial analysis a single serum dilution was chosen to allow a comparative analysis of all the sera obtained from that experiment. Each serum was tested in duplicate; the results shown in the figures are the average of the two results.
Tris-tricine polyacrylamide gel electrophoresis (PAGE)
PEG-precipitated phage samples were mixed with an equal volume of 4% SDS, 20% glycerol, 100 mM Tris-HCl, pH 8.3, 0.1% bromphenol blue and heated to 100°C for 2 min. The samples were subjected to electrophoresis on a 15% PAGE gel with a 5% stacking gel, using a 100 mM Tricine, 100 mM Tris, 0.1% SDS buffer, according to the method described by Willis et al. (1993) . Bands were visualised using the Sigma Silver staining kit.
Analysis of the antigenicity of phage clones by ELISA
Phage were analysed for their reactivity with the relevant mAbs as described previously (Grabowska et al., 1999) . Briefly, PEG precipitated phage were captured in ELISA wells using a rabbit anti-fd polyclonal antibody (Sigma), then incubated in turn with the relevant mAb and a horseradish peroxidase anti-mouse conjugate. The signal was developed as described above.
